Novo Nordisk Partners with OpenAI to Revolutionize Drug Discovery Using AI
Danish pharmaceutical giant Novo Nordisk has struck a landmark deal with OpenAI to embed artificial intelligence across its entire business — from drug discovery to manufacturing and commercial operations. The partnership aims to accelerate obesity and diabetes medication development and could reshape how medicines are created and delivered to patients worldwide by end of 2026.
Read article